Portal de Periódicos da CAPES

A4276 Implantable Bluetooth device for long-term monitoring of left ventricular pressure in small animals

2018; Lippincott Williams & Wilkins; Volume: 36; Linguagem: Inglês

10.1097/01.hjh.0000548035.66776.72

1473-5598

Qing Wang, Medard Rieder, Alexandre Ganchinho, Patrice Rudaz,

Wireless Body Area Networks

Objectives: To date, different wireless blood pressure monitoring systems have been widely applied to rats and mice for medical research. But, they are non-flow through systems and it is impossible to perfuse drug and collect blood sample directly though the device. Furthermore, they exhibit insufficient flat frequency and signal damping. Thus, the goal of this study is to develop a flow-through Bluetooth (BT) implant for monitoring of left ventricular pressure (LVP) in small animals. Methods: The implantable flow-through BT-LVP device consists of a BT pressure sensor chip, a bubble-free fluid chamber, an implantable catheter, and a minipump for drug perfusion and blood sampling. A minimal dose of heparin (1.3Unit/hr.) was perfused via the minipump. The device implantation was performed under 1.5% Isofluthane and 1.5 litter of oxygen per min. The catheter tip was inserted into the left ventricle of an adult normotensive Wistar rat via the carotid artery and fixed. The device body was implanted subcutaneously at the chest side of the rat. The LVP was then monitored in the freely moving rat during the implantation period. Results: The figure shows real-time monitoring of LVP at a sampling rate of 475 Hz by BT-LVP device on day-1 and day-7 after implantation in a freely moving rat. The implantation period of the BT-LVP device can last for one month by 20 second sampling per hour. Conclusion: This initial prototype of a flow-through BT-LVP monitory system will be further validated in mouse and rat models of heart failure and hypertension. It should become a useful tool for studying the pathophysiology and drug therapy in heart failure and hypertension in animal. Potentially it could be later adapted for heart failure patient as well. The work was supported by a Suisse Fonds pour la recherche thérapeutique